David L. Veenstra, PharmD, PhD
Articles
October 14th 2021
Reimbursement for Genetic Variant Reinterpretation: Five Questions Payers Should Ask
David L. Veenstra, PharmD, PhD John W. Rowe, MD José A. Pagán, PhD H. Shelton Brown, PhD John E. Schneider, PhD Avni Gupta, BDS, MPH Sara M. Berger, MS, CGC Wendy K. Chung, MD, PhD Paul S. Appelbaum, MD
Periodic reinterpretation of genetic sequencing results presents a challenge for developing transparent and systematic coverage and reimbursement policies.
January 19th 2012
Systematic Review of Comparative Effectiveness Data for Oncology Orphan Drugs
Mindy M. Cheng, MS Scott D. Ramsey, MD, PhD Emily Beth Devine, PharmD, MBA, PhD Louis P. Garrison, PhD Brian W. Bresnahan, PhD David L. Veenstra, PharmD, PhD
This study critically assessed the published clinical and economic evidence supporting oncology orphan drugs marketed in the United States.
Latest Updated Articles
Published: November 15th 2024 | Updated: November 19th 2024
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Published: April 1st 2024 | Updated: November 5th 2024
What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues
Published: October 21st 2024 | Updated: October 24th 2024
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
Published: September 26th 2024 | Updated: October 1st 2024
Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health
Published: May 9th 2024 | Updated: May 21st 2024
FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors
Published: November 21st 2024 | Updated: November 23rd 2024
Polygenic Risk Scores Can Identify Patients Who Should Receive IOP-Lowering Treatment
